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The reaction of 1,4,5-trisubstituted imidazol-3-oxides 1 with 2,2-
bis(trifluoromethyl)ethene-1,1-dicarbonitrile (7, BTF) yielded the corresponding imidazol-2-
ones 10 and 2-(imidazol-2-ylidene)malononitriles 11, respectively, depending on the solvent 
used. In one example, a 1:1 complex, 12, of the imidazol-3-oxide and hexafluoroacetone 
hydrate was isolated as a second product. The formation of the products is explained by a 
stepwise 1,3-dipolar cycloaddition and subsequent fragmentation. The structures of 11d and 12 
were established by X-ray crystallography. 
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1. INTRODUCTION. - Imidazole N-oxides are interesting compounds with respect to 
their applications as building blocks of imidazole derivatives [1-3] and for their diverse 
biological activities [4-6]. Convenient syntheses of 2-unsubstituted imidazole N-oxides are 
condensations of α-(hydroxyimino)ketones with in situ generated methylidenamines [7], of α-
aminooximes with orthoformates [8], and of diimines with formaldoxime [9]. Generally, 
imidazole N-oxides are not available by direct oxidation of the parent compound. However, a 
recent paper describes the preparation of 1-methylimidazole N3-oxide by treatment of 1-
methylimidazole in THF with H2O2 at room temperature [10]. Starting with imidazole N-
oxides, preparations of imidazole-2-thiones [7], 2-cyanoimidazoles [11], as well as parent 
imidazoles via deoxygenation with PCl3 [12] were reported. Furthermore the isomerization to 
give imidazol-2-ones can easily be achieved by treatment with Ac2O [11] or photochemically 
[13]. 
 
The structure of 2-unsubstituted imidazole N-oxides relates to aldonitrones, which are 
well known 1,3-dipoles. In fact, they react with dipolarophiles, such as dimethyl 
acetylenedicarboxylate [2] [12], isocyanates and isothiocyanates [2], as well as with 
thioketones and thioketenes [7] to give ultimate products, which result from subsequent 
conversions of the initially formed [2+3]-cycloadducts. Of special mechanistic interest is the 
reaction of 1a with thioketene 2, in which the formation of two sets of products, i.e. 3/4 and 5/6 
is an indication for the stepwise reaction pathway [7] (Scheme1). The addition of the dipole 1 to 
the heterocumulene 2 leads to the zwitterionic intermediate A, in which the formation of the 
five-membered unstable cycloadducts (route a) competes with the cyclization to yield thiirane 4 
(route b).  
 
Scheme 1 
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Cycloreversion of the cycloadduct leads to 5 and 6. These results prompted us to test 
other dipolarophiles in reactions with imidazole N-oxides of type 1. The electron deficient 2,2-
bis(trifluoromethyl)ethene-1,1-dicarbonitrile (7, BTF) was selected for the present study. 
 
Apart from the fact that 7 has been used extensively in Diels-Alder reactions [14] and in 
[2+2]-cycloadditions [15], to the best of our knowledge no [2+3]-cycloadditions with this 
dipolarophile have been reported. 
 
2. RESULTS AND DISCUSSION. - Following the previously described procedure, five 
known and three new imidazole N-oxides of type 1 were prepared by heating mixtures of α-
(hydroxyimino)ketones 8 and the corresponding hexahydro-1,3,5-triazines 9, the trimers of 
methylenamines, in EtOH (Scheme 2). 
 
Scheme 2 
 
All prepared compounds 1b-1i were isolated as colorless crystals, which contained 
variable amounts of H2O. The removal of H2O was neither possible by drying under reduced 
pressure nor by azeotropic distillation with toluene, because of the thermal instability of 1, 
which converted into the corresponding imidazol-2-ones. The imidazole N-oxide hydrates of 
type 1.H2O showed a characteristic singlet at ca. 7.8-8.2 ppm in the 1H-NMR spectra. When the 
spectra were recorded from a solution in CD3OD, the signal disappeared after several h at room 
temperature (H/D exchange)2). 
                                                          
2)  Very fast H/D exchange was observed in basic aqueous solution, whereas it was slow in the 
presence of DCl [8]. 
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As pointed out in the introduction, the transformation of N-oxides of type 1 into the 
parent imidazoles was typically carried out by treatment with PCl3 [1][3][12]. In our laboratory, 
N-oxides 1 were deoxygenated by using freshly prepared Raney-Ni [16] in EtOH at room 
temperature and the corresponding imidazoles were obtained in almost quantitative yield. 
 
The first experiments with BTF (7) were carried out in CH2Cl2 using the N-oxides 1 as 
hydrates. The conversions were completed within ca. 15 min at room temperature. The major 
product obtained in these reactions was the corresponding imidazol-2-one 10 (Scheme 3). In 
addition, small amounts of (1,3-dihydroimidazol-2-ylidene)malononitriles 11 were detected. 
Carrying out the same reaction in MeOH solution, compounds 11 were formed as the main 
products. Fractional crystallization of the mixtures gave 11 as colorless or pale yellow crystals. 
Unexpectedly, in the experiment with 1d, in addition to 11d, the complex of the starting 
material with hexafluoroacetone hydrate, depicted as structure 12 in Scheme 3, was isolated by 
concentration of the mother liquor and recrystallization of the residue from CH2Cl2.  
 
Scheme 3 
 
Imidazol-2-ones of type 10 are well documented compounds and the identification of 
10b-10i was possible on the basis of their spectroscopic and analytical data as well as by 
comparison with original samples. The malonodinitrile derivatives 11 are less well known. 
Their IR-spectra (KBr) show two intense absorption bands of the CN groups located at ca. 
2195 and 2155 cm-1. In the 13C-NMR spectra ((D6)DMSO or CDCl3), the C-atoms of the 
exocyclic formal C,C-double bond absorb at 148–146 ppm (C(2)) and 26–23 ppm (=C(CN)2), 
which is characteristic of this type of ‘push-pull’ system [17][18]. These chemical shifts 
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indicate a highly zwitterionic character of these compounds in solution, resulting in a low 
rotational barrier about the exocyclic C=(CN)2 bond [17]. In accordance with this interpretation 
is the fact that only one CN signal appears in the 13C-NMR spectrum.  In the case of 12, the IR 
spectrum showed the presence of a series of strong and broad absorption bands between 3400 
and 2374 cm–1, which were attributed to the associated O-H bonds. Another strong absorption 
at 1213 cm-1 revealed the presence of the CF3 group. In the 1H-NMR spectrum recorded from a 
solution in CD3OD, the characteristic signal of H-C(2) of the imidazole ring ocurred at 8.48 
ppm and was downfield shifted compared with the corresponding signal in 1d.  
 
Finally, the molecular structures of 11d and 12 were established by single crystal X-ray 
diffraction analysis (Figs. 1 and 2). 
 
Fig. 1. ORTEP Plot [19] of the molecular structure of 11d (arbitrary numbering of the atoms; 
50% probability ellipsoids) 
 
The asymmetric unit in the structure of 11d contains one molecule of the heterocycle plus 
one highly disordered MeOH molecule. The disorder of the MeOH molecule could not be 
modelled adequately. Therefore, the contribution of the solvent molecules to the intensity data 
was removed by using the SQEEZE [20] routine of the PLATON program [21]. The NH group 
of 11d forms an intermolecular H-bond with the N-atom of one of the CN groups of a 
neighboring molecule. In turn, the acceptor molecule donates the same type of H-bond back to 
the original molecule, therefore forming centrosymmetric dimers where the H-bonds form a 
closed loop with a graph set motif [22] of R2,2(12). The five-membered heterocycle is almost 
planar, and the adjacent atoms C(13), C(16) and C(22) deviate only slightly from this plane. 
The intraannular C,N-bonds (N1),C(2) and N(3),C(2) are short (1.349(2) and 1.346(2) Å, 
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resp.); the bond lengths are close to those of C=N-bonds (ca. 1.30 Å). Similarly, the C,C-bonds 
to the C≡N groups, i.e. C(13),C(14) and C(13),C(15) show significant double-bond character 
(1.406(2) and 1.408(2) Å, resp.). On the other hand, the formal C82),C(13) double-bond is 
rather long (1.426(2) Å). These data support a zwitterionic structure with the positive charge 
delocalized between N(1),C(2) and N(3), and the negative one between CN(14), C(13), and 
CN(15). Surprisingly, the plane of the malononitrile moiety is twisted only slightly out of the 
heterocyclic plane (dihedral angle N(1) –C(2) –C(13) –C(14) –15.7°). 
 
Fig. 2. a) ORTEP Plot [19] of the molecular structure of 12 (arbitrary numbering of the atoms; 
50% probability ellipsoids) and b) Packing diagram 
 
There is one molecule of the zwitterionic oxide and one molecule of hexafluoropropane-
2,2-diol (hexafluoroacetone hydrate) in the asymmetric unit of structure 12. The OH groups 
form intermolecular H-bonds with the oxide O-atom of two different zwitterions, so that each 
zwitterions accepts a H-bond at the same atom from two different ketone hydrates. These 
interactions together link two zwitterions and two ketone hydrates to give centrosymmmetric 
tetramers where the H-bonds form a closed loop with a graph set motif of R2,4(12). 
 
Formula 
 
Reaction mechanisms for the formation of the imidazole derivatives 10-12 are proposed 
in Scheme 4. The key intermediate is the zwitterion B, which is formed by a nucleophilic 
addition of 1 onto 7. In CH2Cl2, B reacts with the H2O of the hydrate to give C, which 
undergoes a subsequent fragmentation to yield 10. As the second product, we postulate the 
adduct 13 of H2O and 7, which, however, could not be detected after workup. The conversion 
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of B to 11 in MeOH solution occurs via a 1,5-dipolar electrocyclization which yields the 
‘cycloadduct’ D. Subsequent cleavage of the N,O bond followed by a retro-ene reaction leads 
finally to 11 and hexafluoroacetone, which is immediately captured by H2O. The different 
reaction course in CH2Cl2 and in MeOH is remarkable. A likely interpretation is the higher 
nucleophilicity of H2O in an aprotic solvent like CH2Cl2 compared with MeOH, which reduces 
the nucleophilicity by solvatation. 
 
Scheme 4 
 
As shown in Scheme 4, H2O plays an important role in the formation of products in the 
reaction of 1 and 7. For this reason, the reaction was repeated using anhydrous N-oxides 1, 
which were prepared by drying the corresponding hydrates with activated molecular sieves in 
CHCl3. Under these conditions, the (imidazol-2-ylidene)malononitriles 11 were formed in high 
yield (Scheme 4). Neither imidazol-2-ones 10 nor complexes of type 12 were present in the 
reaction mixtures. 
In conclusion, the present study shows that imidazole N-oxides 1 easily react with BTF 
(7). Although the formation of products 11 can be explained via a formal [2+3]-cycloaddition, 
the formation of imidazol-2-ones 10 (in the reaction involving H2O) clearly indicate a stepwise 
reaction mechanism. The common intermediate in the formation of all products is the 
zwitterion B, which is the product of the regioselective attack of the ‘nitrone-like’ dipolar 
species 1 on 7. This reaction can be regarded as the initial step of a Michael addition, thus 
leading to the activation of C(2) of the imidazolium ring. In the light of these results, the 
combination 1/7 fulfils the fundamental requirement for a step-wise course of a [2+3]-
cycloaddition i.e. an electron-rich 1,3-dipole approaches an electron deficient dipolarophile 
[23][24]. 
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The formation of 11 under anhydrous conditions can be of preparative importance as 
derivatives of (1,3-dihydroimidazol-2-ylidene)malononitriles are known as pharmacologically 
active compounds [25]. 
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Experimental Part 
 
1. General. M.p.s: Melt-Temp. II apparatus (Aldrich); in capillary; uncorrected. IR 
spectra (KBr): NEXUS FT-IR spectrophotometer; in KBr. 1H- and 13C-NMR spectra: Tesla 
BS567A (80 and 20 MHz, resp.) or Bruker AC 300 instrument (300 and 75.5 MHz, resp.); in 
CDCl3, TMS as an internal standard. The multiplicity of the 13C signals was deduced from the 
DEPT spectra. MS (EI or CI): Finnigan MAT-90 or Finnigan SSQ-700 instruments. Elemental 
analyses were performed in the Analytical Laboratory of the University of Zürich or in the 
Laboratory of the Polish Academy of Sciences (CBMiMM) in Łódź. 
2. Starting materials. α-Hydroxyiminoketones 8 were obtained according to known 
protocols: R1 = Me [26], R1 = Ph [27]. 1,3,5-Trisubstituted hexahydro-1,3,5-trizines 9 were 
prepared following known methods: R2 = Me [28], R2 = Bn [29], R2 = cHex [30], R2 = cProp 
[31], and R2 = Allyl [32].  
3. Preparation of 1H-Imidazole 3-Oxides (1): Syntheses and properties of the N-oxides 
1b-f have already been described [7][11][33]. Compounds 1g-i, which have not been described 
so far, were prepared by heating 1.2 mmol of the corresponding 1,3,5-hexahydrotriazine 9 with 
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1.0 mmol of 3-(hydroxyimino)-3-phenylpropan-2-one (8, R1 = Me) and α-benzil monoxime (8, 
R1 = Ph), respectively, in boiling EtOH. After removal of the solvent in vacuo, the resulting 
mixture was treated with Et2O, cooled, then the product was filtered, washed with cold acetone 
and recrystallized. In the case of 1-allyl-4,5-diphenyl-1H-imidazole 3-oxide (1i), the reaction 
mixture also contained the isomeric 1,3-dihydro-2H-imidazol-2-one, which was formed as a 
side product, and the separation of both compounds was achieved by column chromatography 
(SiO2, AcOEt). 
1-Cyclopropyl-5-methyl-4-phenyl-1H-imidazole 3-Oxide (1g): 3 h; yield: 199 mg (93%). 
Colorless needles. M.p. 172–174º (acetone). IR: 3063s, 3020m, 2961s (br.), 1619m (br.), 
1594m, 1497m, 1445m, 1422s, 1386vs, 1374vs, 1317m, 1258m, 1219s, 1150m, 1064w, 1036m, 
894m, 843m, 825s, 769m, 755s, 697s (br.). 1H-NMR: 7.27 (s, H–C(2)); 6.78–6.76, 6.60–6.47 
(2m, 5 arom. H); 2.36–2.31 (m, 1 H of cProp); 1.50 (s, Me); 0.29–0.15 (m, 4 H of cProp). 13C-
NMR: 129.9, 127.0, 124.4 (3s, arom. Cq, C(4), C(5)); 129.4, 128.2, 128.1 (3d, 5 arom. CH); 
125.6 (d, C(2)); 27.0 (d, CH of cProp); 9.7 (q, Me); 6.42 (t, 2 CH2 of cProp). EI-MS: 214 (100, 
M+.), 198 (62), 197 (67), 130 (30). Anal. calc. for C13H14N2O.1/8 H2O (216.52): C 72.12, H 
6.63, N 12.94; found: C 72.09, H 6.57, N 12.93. 
1-Allyl-5-methyl-4-phenyl-1H-imidazole 3-Oxide (1h): 2 h; yield: 191 mg (89%). 
Colorless crystals. M.p. 164–167º (CH2Cl2/Et2O). IR: 3093w, 3063s, 3031m, 2980s, 2940vs, 
1640m, 1626m, 1497m, 1456m, 1428s, 1384vs, 1361m, 1348m, 1317m, 1268s, 1220s, 1142w, 
932s, 852m, 836m, 762s, 719s, 699s. 1H-NMR: 7.91 (s, H-C(2)); 7.68–7.31 (m, 5 arom. H); 
5.97–5.84 (m, –CH=); 5.35–5.12 (m, =CH2); 4.48–4.46 (m, CH2N); 2.23 (s, Me). 13C-NMR: 
131.3 (d, –CH=); 130.5, 127.4, 122.5 (3s, arom. Cq, C(4), C(5)); 129.7, 128.4, 128.2 (3d, 5 
arom. CH); 124.9 (d, C(2)); 119.1 (t, =CH2); 48.0 (t, CH2); 9.3 (q, Me). CI-MS: 215 (100, 
[M+1]+), 199 (39). Anal. calc. for C13H14N2O (214.27): C 72.87, H 6.59, N 13.07; found: C 
72.68, H 6.57, N 13.09. 
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1-Allyl-4,5-diphenyl-1H-imidazole 3-Oxide (1i): 5 h; yield: 201 mg (73%). Colorless 
solid. M.p. 176–180º (CH2Cl2/Et2O). IR: 3065s, 3024m, 2991s, 2975s, 2935m, 1621m (br.), 
1603m, 1585m, 1585m, 1507m, 1483s, 1458m, 1445s, 1423m, 1328s, 1344s, 1320m, 1306m, 
1269m, 1208m, 1183m, 1077m, 1051m, 1024m, 993m, 955m, 944m, 930m, 814m, 769vs, 
715vs, 704vs, 698vs. 1H-NMR: 8.07 (s, H-C(2)); 7.58–7.24 (m, 10 arom. H); 5.93–5.80 (m, –
CH=); 5.33–5.15 (m, =CH2); 4.42–4.40 (m, CH2N). 13C-NMR: 131.7 (d, –CH=); 130.7, 129.6, 
129.1, 128.1 (4d, 10 arom. CH); 130.8, 127.4, 127.1, 127.0 (4s, 2 arom. Cq, C(4), C(5)); 125.8 
(d, C(2)); 119.6 (t, =CH2); 48.3 (t, CH2). CI-MS: 277 (63, [M+1]+), 261 (100). Anal. calc. for 
C18H16N2O (276.34): C 78.24, H 5.84, N 10.14; found: C 78.10, H 5.85, N 10.11. 
3. Deoxygenation of Imidazole N-Oxides 1 with Raney-Ni. – General procedure. To a 
magnetically stirred soln. of 1b (188 mg, 1.0 mmol) in EtOH (2 ml), a suspension of freshly 
prepared Raney-Ni [16] in EtOH was added portion-wise in intervals of ca. 10 min until the 
conversion of the starting material was complete (TLC). Then, the mixture was filtered in order 
to remove the black Ni precipitate and the filtrate was evaporated to dryness. Imidazole 3b was 
obtained as pure material (1H-NMR). Analogous treatment of 1d with Raney-Ni at r.t. yielded 
pure 3d.  
1,5-Dimethyl-5-phenyl-1H-imidazole (3b): Yield: 165 mg (96%). Colorless oil [34]. IR 
(neat): 3150–2850m (br.), 1717m, 1663m, 1604s, 1580m, 1563w, 1508s, 1495s, 1472m, 1444s, 
1423m, 1379s, 1320w, 1303w, 1239s, 1165m, 1138m, 1071m, 1012m, 939m, 772s, 739m, 703s, 
632s. 1H-NMR: 7.73–7.10 (m, H–C(2), 5 arom. H); 3.57 (s, MeN); 2.38 (s, Me). 
1-Benzyl-4,5-diphenyl-1H-imidazole (3d): Yield: 300 mg (97%). Colorless solid. M.p. 
112–115º ([35]: 113–115º). IR: 3150–2950m (br.), 1602s, 1506s, 1497s, 1477m, 1455s, 1443s, 
1433m, 1359s, 1254s, 1193m, 1068m, 1027m, 955s, 915m, 828m, 794s, 774s, 760vs, 724vs, 
698vs, 668m, 654s. 1H-NMR: 7.81 (s, H–C(2)); 7.67–6.75 (m, 15 arom. H); 4.98 (s, PhCH2). 
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4. Synthesis of 1,3-Dihydro-2H-imidazol-2-ones (10). – General Procedure. To a 
magnetically stirred soln. of 1.0 mmol imidazole-3-oxide 1 (hydrates with variable amounts of 
H2O) in ca. 10 ml of CH2Cl2, a soln. of 2,2-bis(trifluoromethyl)ethane-1,1-dicarbonitrile (7, 
BTF) (235mg, 1.1 mmol) in CH2Cl2 (4 ml) was added dropwise at r.t. and stirring was 
continued for 20 min. Then, the solvent was evaporated and the semi-solid residue was 
triturated with Et2O to give a colorless, crystalline material, which was identified as 10, 
contaminated with traces of the corresponding 11. Purification of the main product was 
achieved by crystallization from MeOH or from a mixture of hexane and CH2Cl2. 
1,3-Dihydro-1,5-dimethyl-4-phenyl-2H-imidazol-2-one (10b): Yield: 118 mg (63%). 
Colorless crystals. M.p. (decomp.) 246–249º (MeOH; [11]: 246–251º). IR: 3200–2800m (br., 
NH), 1675vs (C=O), 1599m, 1503m, 1468m, 1434m, 1396m, 1384m, 845m, 766m, 745m, 
700m, 666m. 1H-NMR (CD3OD): 7.48–7.15 (m, 5 arom. H); 3.22 (s, MeN); 2.21 (s, Me). 
1,3-Dihydro-1-methyl-4,5-diphenyl-2H-imidazol-2-one (10c): Yield: 182mg (73%). 
Colorless crystals. M.p. (decomp.) 284–287º (MeOH; [11]: 286–290º). IR: 3200–2640m (br. 
NH); 1679vs (C=O); 1604s, 1507s, 1455s, 1432m, 1390s, 1024m, 955m, 866m, 834m, 768s, 
746m, 723m, 698s, 668m. 1H-NMR: 9.53 (br. s, NH); 7.55-7.25 (m, 5 arom. H); 7.16 (br. s, 5 
arom. H); 3.14 (s, Me). 
1-Benzyl-1,3-dihydro-4,5-diphenyl-2H-imidazol-2-one (10d): Yield: 257 mg (79%). 
Colorless crystals. M.p. (decomp.) 221–226º (MeOH; [31]: 176–178º). IR: 3200–2800s (br., 
NH), 1686vs (C=O), 1604m, 1508m, 1497m, 1445s, 1400s, 1345m, 1075w, 935w, 769s, 746m, 
720m, 696s, 667m. 1H-NMR (CD3OD): 7.36–6.87 (m, 10 arom. H); 7.17 (br. s, 5 arom. H); 
4.78 (s, CH2N). 
1-Cyclohexyl-1,3-dihydro-4,5-diphenyl-2H-imidazol-2-one (10f): Yield: 229 mg (72%). 
Colorless crystals. M.p. (decomp.) 287–290º (EtOH; [11]: 286–290º). IR: 3200–2800s (br., 
NH), 1674vs (C=O), 1603m, 1507m, 1444m (br.), 1375s, 1351m, 800m, 763s, 752m, 702s, 
13 
692s, 666m. 1H-NMR (CD3OD): 7.58–7.24 (m, 5 arom. H); 7.12 (br. s, 5 arom. H); 3.65–3.43 
(m, 1H, cHex); 2.55–0.80 (m, 10 H of cHex). 
1-Cyclopropyl-1,3-dihydro-5-methyl-4-phenyl-2H-imidazol-2-one (10g): Yield: 154 mg 
(72%). Colorless crystals. M.p. (decomp.) 198–200º (CH2Cl2/hexane). IR: 3150–2750m (br., 
NH), 1679vs (C=O), 1642m, 1602m, 1504m, 1456m, 1414m, 1374m, 1032m, 835m, 763s, 747s, 
698m. 1H-NMR: 9.62 (br. s, NH); 7.43–7.22 (m, 5 arom. H); 2.74–2.67 (m, 1 H of cProp); 2.32 
(s, Me); 1.04–1.01 (m, 4 H of cProp). 13C-NMR: 154.8 (s, C=O); 130.5, 117.7, 117.2 (3s, arom. 
Cq, C(4), C(5)); 128.8, 126.7, 126.1 (3d, 5 arom. CH); 22.9 (d, CH of cProp); 10.3 (q, Me); 6.7 
(t, 2 CH2 of cProp). CI-MS: 216 (14), 215 (100, [M+1]+), 214 (5, M+.). Anal. calc. for 
C13H14N2O (214.27): C 72.87, H 6.59, N 13.07; found: C 71.75, H 6.09, N 12.72. 
1-Allyl-1,3-dihydro-5-methyl-4-phenyl-2H-imidazol-2-one (10h): Yield: 141 mg (66%). 
Colorless crystals. M.p. (decomp.) 183–184º (MeOH). IR: 3200–2650m (br., NH), 1694vs 
(C=O), 1640s, 1599m, 1503m, 1458m, 1430m, 1408s, 1386m, 1345m, 937m, 923m, 843m, 
764s, 741s, 701m, 669m. 1H-NMR: 10.68 (br. s, NH); 7.44–7.20 (m, 5 arom. H); 5.98–5.85 (m, 
–CH=); 5.20–5.09 (m, =CH2); 4.35–4.32 (m, CH2); 2.22 (s, Me). 13C-NMR: 154.1 (s, C=O); 
133.4 (d, –CH=); 128.7, 126.5, 126.0 (3d, 5 arom. CH); 130.4, 117.8, 115.8 (3s, arom. Cq, 
C(4), C(5)); 116.2 (t, =CH2); 42.8 (t, CH2); 9.7 (q, Me). CI-MS: 215 (100, [M+1]+), 214 (5, 
M+.), 188.2 (8). Anal. calc. for C13H14N2O (214.27): C 72.87, H 6.59, N 13.07; found: C 72.87, 
H 6.53, N 12.98. 
1-Allyl-1,3-dihydro-4,5-diphenyl-2H-imidazol-2-one (10i): Yield: 226 mg (82%). 
Colorless crystals. M.p. (decomp.) 218–221º (MeOH). IR: 3200–2800m (br., NH), 1682vs 
(C=O), 1647m, 1571m, 1507w, 1444w, 1430w, 1394m, 1370w, 1358w, 1143w, 939w, 921w, 
768m (br.), 705m, 694m, 667m. 1H-NMR ((D6)DMSO): 10.84 (br. s, NH); 7.51–7.20 (m, 10 
arom. H); 5.79–5.66 (m, –CH=); 5.07–4.82 (m, =CH2); 4.10–4.05 (m, CH2N). 13C-NMR: 152.8 
(s, C=O); 133.8 (d, –CH=); 130.5, 128.8, 128.7, 128.2, 126.4, 125.3 (6d, 10 arom. CH); 129.5, 
14 
120.3, 117.2 (3s, 2 arom. Cq, C(4), C(5)); 115.7 (t, =CH2); 42.3 (t, CH2). CI-MS: 277 (100, 
[M+1]+), 276 (18), 235 (5). Anal. calc. for C18H16N2O (276.34): C 78.24, H 5.84, N 10.14; 
found: C 77.89, H 5.76, N 10.15. 
5. Synthesis of 2-(1,3-Dihydroimidazol-2-ylidene)malononitriles (11). – General 
Procedure. To a stirred soln. of 1.0 mmol imidazole-3-oxide 1 (anhydrous form, obtained by 
drying over freshly activated molecular sieves 4Å) in ca. 10 ml of dry CHCl3, a soln. of 7 (235 
mg, 1.1 mmol) in CHCl3 (3 ml) was added dropwise at r.t. and stirring was continued for 20 
min. The solvent was evaporated i.v., and the residue was triturated with ca. 3 ml of Et2O. The 
colorless solid was filtered and purified by recrystallization from MeOH.  
2-(1,3-Dihydro-1,5-dimethyl-4-phenylimidazol-2-ylidene)malononitrile (11b). Yield: 111 
mg (47%). Pale violet crystals. M.p. (decomp.) 219-223º (MeOH). IR: 3250–2800s (br., NH), 
2198vs (CN), 2157vs (CN), 1640m, 1589vs (C=C(CN)2), 1503m, 1488s, 1442m, 1421m, 
1218w, 1141w, 767s, 697s. 1H-NMR ((D6)DMSO): 7.48 (br. s, 5 arom. H); 3.57 (s, MeN); 2.24 
(s, Me). 13C-NMR ((D6)DMSO): 146.1 (s, C=C(CN)2); 128.6, 128.2, 127.9 (3d, 5 arom. CH); 
124.7 124.1 (2s, arom. Cq, C(4), C(5)); 120.3 (s, C=C(CN)2); 31.5 (q, MeN); 22.4 (s, 
C=C(CN)2); 9.0 (q, Me). EI-MS: 236 (100, M+.), 221 (27), 196 (69), 130 (23), 77 (24). 
2-(1-Benzyl-1,3-dihydro-4,5-diphenylimidazol-2-ylidene)malononitrile (11d). Yield: 182 
mg (49%). Pale yellow crystals. M.p. (decomp.) 198-203º (MeOH). IR: 3200–2800m (br., NH), 
2198vs (CN), 2164vs (CN), 1640m, 1597m, 1580vs (C=C(CN)2), 1506w, 1497w, 1470m, 
1452m, 1431m, 1344w (br.), 1227w, 769m, 731m, 698s. 1H-NMR: 11.28 (br. s, NH); 7.47–6.96 
(m, 10 arom. H); 7.25 (br. s, 5 arom H); 5.23 (s, CH2). 13C-NMR: 148.4 (s, C=C(CN)2); 135.1 
(s, arom. Cq); 131.0, 130.0, 129.2, 128.7, 128.6, 127.9, 127.1, 126.4 (8d, 15 arom. CH); 127.7, 
126.7, 126.6, 126.5 (4s, 2 arom. Cq, C(4), C(5)); 119.5 (s, C=C(CN)2); 47.6 (t, CH2); 26.7 (s, 
C=C(CN)2). CI-MS: 376 (29), 375 (100, [M+1]+), 285 (9). 
15 
Suitable crystals for the X-ray crystal structure determination of 11d were obtained from 
MeOH by slow evaporation of the solvent. 
2-(1-Cyclohexyl-1,3-dihydro-5-methyl-4-phenylimidazol-2-ylidene)malononitrile (11e). 
Yield: 133 mg (44%). Colorless needles. M.p. (decomp.) 255-256º (MeOH). IR: 3200–2850s 
(br., NH), 2196vs (CN), 2156vs (CN), 1645m, 1599m, 1570vs (C=C(CN)2), 1496w, 1457m, 
1439m, 1340w, 1273w, 1237w, 818w, 769m, 701m. 1H-NMR ((D6)DMSO): 7.47 (br. s, 5 arom. 
H); 4.49–4.35 (m, 1 H of cHex); 2.36 (s, Me); 2.06–1.85, 1.70–1.62, 1.41–1.19 (3m, 10 H of 
cHex). 13C-NMR ((D6)DMSO): 146.0 (s, C=C(CN)2); 128.5, 128.4 (2d, 5 arom. CH); 127.6, 
126.8, 123.3 (3s, arom. Cq, C(4), C(5)); 120.9 (s, C=C(CN)2); 57.7 (d, CH of cHex); 30.7, 25.7, 
21.2 (3t, 5 CH2 of cHex); 24.3 (s, C=C(CN)2); 11.4 (q, Me). EI-MS: 304 (11, M+.), 222 (100), 
197 (10), 77 (18), 55 (33). 
2-(1-Cyclohexyl-1,3-dihydro-4,5-diphenylimidazol-2-ylidene)malononitrile (11f). Yield: 
193 mg (53%). Colorless crystals. M.p. (decomp.) 278-285º (MeOH). IR: 3250–2800s (br., 
NH), 2198vs (CN), 2161vs (CN), 1636m, 1596s, 1572vs (C=C(CN)2), 1504m, 1451s, 1435s, 
1407m, 1336w, 1226w, 1224m, 1111w, 1074w, 1018w, 894w, 792m, 773s, 749m, 700vs. 1H-
NMR: 7.55–7.07 (m, 10 arom. H); 4.43–4.33 (m, 1 H of cHex); 1.95–0.77 (m, 10 H of cHex). 
13C-NMR: 148.8 (s, C=C(CN)2); 133.1, 131.3, 130.2, 129.8, 128.6 (5d, 10 arom. CH); 132.6, 
130.0, 128.9, 127.0 (4s, arom. Cq); 122.5 (s, C=C(CN)2); 61.3 (d, CH of cHex); 33.9, 27.2, 25.9 
(3t, 5 CH2 of cHex); 24.8 (s, C=C(CN)2). CI-MS: 368 (28), 367 (100, [M+1]+), 342 (6), 319 
(5). Anal. calc. for C24H22N4 (366.47): C 78.66, H 6.05, N 15.29; found: C 78.37, H 6.02, N 
15.25. 
2-(1-Cyclopropyl-1,3-dihydro-5-methyl-4-phenylimidazol-2-ylidene)malononitrile (11g). 
Yield: 120 mg (46%). Pale yellow crystals. M.p. (decomp.) 241-244º (MeOH). IR: 3250–2850s 
(br., NH), 2193vs (CN), 2155vs (CN), 1647m, 1603m, 1575vs (C=C(CN)2), 1503s, 1473m, 
1447m, 1435m, 1416m, 1369m, 1330w (br.), 1229w, 1107w, 1038m, 1012w, 843m, 769s, 742m, 
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710m, 696s, 666m. 1H-NMR ((D6)DMSO): 7.49–7.44 (m, 5 arom. H); 3.18–3.12 (m, 1 H of 
cProp); 2.31 (s, Me); 1.22–1.09 (2m, 4 H of cProp). 13C-NMR ((D6)DMSO): 148.3 (s, 
C=C(CN)2); 128.5, 128.1, 127.9 (3d, 5 arom. CH); 127.8, 125.1, 124.6 (3s, arom. Cq, C(4), 
C(5)); 120.3 (s, C=C(CN)2); 26.5 (s, C=C(CN)2); 24.1 (d, CH of cProp); 10.2 (q, Me); 10.1 (t, 2 
CH2 of cProp). EI-MS: 262 (67, M+.), 222 (35), 221 (100), 130 (28), 103 (20), 77 (24). 
2-(1-Allyl-1,3-dihydro-5-methyl-4-phenylimidazol-2-ylidene)malononitrile (11h). Yield: 
160 mg (61%). Colorless crystals. M.p. (decomp.) 200-205º (MeOH). IR: 3250–2850s (br., 
NH), 2194vs (CN), 2153vs (CN), 1646s, 1579vs (C=C(CN)2), 1504s, 1475s, 1444m, 1433m, 
1414m, 1320m, 1288w, 1272w, 1229w, 1154w (br.), 988m, 934m, 923w, 791m, 769s, 698s. 1H-
NMR ((D6)DMSO): 12.75 (br. s, NH); 7.49–7.37 (m, 5 arom. H); 6.02–5.92 (m, –CH=); 5.29–
5.02 (m, =CH2); 4.73–4.72 (m, CH2); 2.21 (s, Me). 13C-NMR ((D6)DMSO): 146.3 (s, 
C=C(CN)2); 132.0 (d, –CH=); 128.5, 128.3, 128.1 (3d, 5 arom. CH); 127.7, 125.0, 123.7 (3s, 
arom. Cq, C(4), C(5)); 120.0 (s, C=C(CN)2); 117.1 (t, =CH2); 45.8 (t, CH2); 23.2 (s, 
C=C(CN)2); 8.7 (q, Me). EI-MS: 262 (47, M+.), 222 (43), 221 (100), 130 (25), 77 (17). 
6. Isolation of the Complex 12. To a soln. of the monohydrate of 1d (344 mg, 1.0 mmol) 
in MeOH (4 ml), a soln. of 7 (235 mg, 1.1 mmol) in MeOH (2 ml) was added dropwise and the 
mixture was stirred magnetically for 20 min at r.t. The solvent was evaporated i.v. and the oily 
residue was triturated with ca. 3 ml of Et2O. The separated solid was dissolved in hot MeOH 
and left to cool. In the refrigerator, crystals of 11d formed. They were filtered and the mother 
liquor was evaporated i.v. to dryness. The colorless residue was dissolved in CH2Cl2 giving, 
after cooling in the refrigerator overnight, analytically pure crystals of the 1:1 complex of 
hexafluoroacetone hydrate and 1-benzyl-4,5-diphenyl-1H-imidazole 3-oxide (12). Yield: 40 mg 
(8%). Colorless prisms. M.p. (decomp.) 116-117° (CH2Cl2). IR: 3450–2360s (br., H-bridged 
OH), 1277m, 1213vs (CF3), 1173s, 1148m, 1093s, 957m, 721s, 698s. 1H-NMR (CD3OD): 8.48 
(s, CH); 7.52–6.84 (m, 15 arom. H); 5.11 s, CH2). 19F-NMR (CD3OD): –83.6 (2 CF3). CI-MS: 
17 
328 (26), 327 (100, [M–C3H2F6O2+1]+). Anal. calc. for C25H20F6N2O5 (510.44): C 58.83, H 
3.95; found C 58.43, H 3.98. 
7. X-Ray Crystal-Structure Determination of 11d and 12 (Table and Figs. 1-2)3). All 
measurements were performed on a Nonius KappaCCD diffractometer [36] using graphite-
monochromated MoKα radiation (λ 0.71073 Å) and an Oxford Cryosystems Cryostream 700 
cooler. The data collection and refinement parameters are given in the Table, and views of the 
molecules are shown in Figs. 1 and 2. Data reduction was performed with HKL Denzo and 
Scalepack [37]. The intensities were corrected for Lorentz and polarization effects but not for 
absorption. Equivalent reflections were merged. The structures were solved by direct methods 
using SIR92 [38], which revealed the positions of all non-H-atoms. The asymmetric unit of 11d 
contains one molecule of the heterocycle and one highly disordered MeOH molecule. The 
disorder of the latter could not be modelled adequately, so the SQUEEZE routine [20] of the 
program PLATON [21] was employed. This procedure, which allows the disordered solvent 
molecules to be omitted entirely from the subsequent refinement model, gave better refinement 
results and there were no significant peaks of residual electron density to be found in the voids 
of the structure. The procedure leaves one cavity of 111 Å3 per unit cell. The electron count in 
the disordered region was calculated to be 26 e per cavity, although this can be an underbound. 
Allowing for two MeOH molecules per cavity (one per asymmetric unit, which corresponds 
with the estimate from the original attempt to model the solvent molecule) yields 36 e and this 
estimate was used in the subsequent calculation of the empirical formula, formula weight, 
density, linear absorption coefficient and F(000). The asymmetric unit of 12 contains two 
chemically distinct moieties. The non-H-atoms of 11d and 12 were refined anisotropically. The 
                                                          
3) CCDC-602037–602038 contain the supplementary crystallographic data for this paper. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre, via 
www.ccdc.cam.ac.uk/data_request/cif. 
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HN-atom of 11d and the HO-atoms of 12 were paced in the positions indicated by a difference 
electron density maps and their positions were allowed to refine together with individual 
isotropic displacement parameters. All remaining H-atoms were placed in geometrically 
calculated positions and refined using a riding model where each H-atom was assigned a fixed 
isotropic displacement parameter with a value equal to 1.2 Ueq of its parent C-atom. The 
refinement of each structure was carried out on F2 using full-matrix least-squares procedures, 
which minimized the function Σw(Fo2 – Fc2)2. Corrections for secondary extinction were 
applied. In each case, two reflections, whose intensities were considered to be extreme outliers, 
were omitted from the final refinement. Neutral atom scattering factors for non-H-atoms were 
taken from [39a], and the scattering factors for H-atoms were taken from [40]. Anomalous 
dispersion effects were included in Fc [41]; the values for f' and f" were those of [39b]. The 
values of the mass attenuation coefficients are those of [39c]. All calculations were performed 
using the SHELXL97 [42] program. 
 
Table. Crystallographic Data for Compounds 11d and 12 
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Table.  Crystallographic Data for Compounds 11d and 12 
__________________________________________________________________________________ 
 
 11d 12 
__________________________________________________________________________________ 
 
Crystallized from MeOH MeOH 
Empirical formula C25H18N4.CH3OH C22H18N2O.C3H2F6O2 
Formula weight 406.49 510.43 
Crystal color, habit colorless, prism colorless, plate 
Crystal dimensions [mm] 0.10 × 0.27 × 0.27 0.05 × 0.20 × 0.37 
Temperature [K] 160(1) 160(1) 
Crystal system triclinic triclinic 
Space group P
_
,1 P  
_
,1
Z 2 2 
Reflections for cell determination 5940 5206 
2θ range for cell determination [°] 4–60 4–55 
Unit cell parameters a [Å] 9.5540(5) 10.5912(4) 
 b [Å] 10.2090(4) 10.8967(4) 
 c [Å] 11.7472(6) 11.6654(5) 
 α [°] 70.527(3) 87.757(3)  
 β [°] 79.331(2) 79.724(3)  
 γ  [°] 77.549(3) 62.052(2)  
 V [Å3] 1046.82(9) 1168.67(8) 
Dx [g cm
-3
] 1.289 1.450 
µ(MoKα) [mm
-1
] 0.0809  0.127 
Scan type φ and ω  φ and ω 
2θ(max) [°] 60 55 
Total reflections measured 25346 26435 
Symmetry independent reflections 6094 5333 
Reflections with I > 2σ(I) 3346 3721 
Reflections used in refinement 6092 5331 
Parameters refined 268 334 
Final R(F)  [I > 2σ (I) reflections] 0.0661  0.0446 
 wR(F
2
)  (all data) 0.1974  0.1155 
Weighting parameters [a; b]a) 0.1065; 0 0.0520; 0.1644 
Goodness of fit 0.995 1.057 
Secondary extinction coefficient 0.048(9) 0.034(3) 
Final ∆max/σ 0.001 0.001 
∆ρ (max; min) [e Å
-3
] 0.37; –0.29 0.20; –0.21 
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a) w-1 = σ 2(Fo2) + (aP)2 + bP  where P = (Fo2 + 2Fc2)/3 
 
 
 
 
 
 
 
 
Legends 
 
 
Fig. 1. ORTEP Plot [19] of the molecular structure of 11d (arbitrary numbering of the atoms; 
50% probability ellipsoids) 
MG 348/04  (HG0446) 
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Fig. 2. a) ORTEP Plot [19] of the molecular structure of 12 (arbitrary numbering of the atoms; 
50% probability ellipsoids) and b) Packing diagram 
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25 
 
 
 
 
 
MG 349/04  (HG0447) 
 
 
 
 
 
 
 
 
 
 
26 
 
 
 
 
S
t-Bu
Scheme 1
i-Pr
5
N
N
Me
Me
O
Bn
N
N
Me
Me
O
Bn
S
i-Pr
t-Bu
a)
b)
N
N
Me
Me
Bn
NH
N
Me
Me
Bn
S
S
t-Bu
i-Pr
O
1a
2
3a 4
6
A
a)
b)
O
t-Bu
i-Pr
27 
 
 
 
 
 
Scheme 2
N
N
Ph
R1
O
R2
1
O
R1 Ph
N OH
N N
N
R2
R2R2
H2O
8 9
EtOH
∆
1b       1c       1d       1e       1f       1g       1h     1i
R1   Me      Ph       Ph       Me      Ph      Me      Me    Ph
R2   Me      Me      Bn     cHex   cHex   cProp   Allyl   Allyl
3
N
N
Ph
R1
O
R2
1
H2O
Scheme 3
7
CH2Cl2
F3C
F3C CN
CN
r.t.
MeOH
r.t.
NH
N
Ph
R1
R2
10
NH
N
Ph
R1
R2
11
N
N
Ph
R1
O
R2
12  (R1 = Ph, R2 = Bn)
(CF3)2C(OH)2
O
CN
CN
28 
 
 
 
Formula 
 
N
N
Ph
R1
O
R2
1
H2O
Scheme 4
7
HO
F3C
H
CN
NH
N
Ph
R1
R2
10
NH
N
Ph
R1
R2
11
(CF3)2CO
O
CN
CN
CF3
CF3
NC
CN N
N
Ph
R1
O
R2
CF3
CF3
NC
CN
OH2
H
N
N
Ph
R1
R2
O
CF3
CF3
CN
CN
H
N
N
Ph
R1
R2
O
CF3
CF3
NC CN
H
E 13
B C
D
F3C
CN
H
O O
O
H
O
H
O
O
H CF3
CF3
N
N
Ph
Ph
Ph
F3C CF3
N
N
Ph
Ph
Ph
